Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Early recovery of circulating immature B cells in B-lymphoblastic leukemia patients after CD19 targeted CAR T cell therapy: A pitfall for minimal residual disease detection
Cytometry Part B - Clinical Cytometry, Volume 94, No. 3, Year 2018
Notification
URL copied to clipboard!
Description
Background: CD19-targeted chimeric-antigen receptor-modified T-cells (CAR-T) are promising in the treatment of refractory B-lymphoblastic leukemia (B-ALL). Minimal residual disease (MRD) detection by multicolor flow cytometry (FCM) is critical to distinguish B-ALL MRD from regenerating, non-neoplastic B-cell populations. Methods: FCM was performed on samples from 9 patients with B-ALL treated with CAR-T. Results: All 9 patients showed response to CAR-T. Additionally, FCM revealed circulating CD10 + B cells, potentially mimicking MRD. Circulating CD10+ B-cells were detected in blood from 3 days to 3 months after CAR-T, comprising 73% (median) of B-cells (52–83%, 95%CI). They expressed CD19, CD10, CD20, bright CD9, CD22, CD24, moderate CD38 and dim CD58, but were CD34 (–), with bright CD45 and polyclonal surface light chain immunoglobulin (sIg) expression. A similar CD10 + B-cell subpopulation was detected by marrow FCM, amidst abundant B-cell precursors. Conclusions: These circulating CD10 + B-cells are compatible with immature B-cells, and are a reflection of B-cell recovery within the marrow. They are immunophenotypically distinguishable from residual B-ALL. Expression of light chain sIg and key surface antigens characterizing regenerating B-cell precursors can distinguish immature B-cells from B-ALL MRD and prevent misdiagnosis. © 2017 International Clinical Cytometry Society.
Authors & Co-Authors
Xiao, Wenbin
United States, Rockville
National Cancer Institute Nci
United States, New York
Memorial Sloan-kettering Cancer Center
Salem, Dalia Abdel Raouf
United States, Rockville
National Cancer Institute Nci
Egypt, Mansoura
Faculty of Medicine
McCoy, Catharine S.
United States, Rockville
National Cancer Institute Nci
Lee, Daniel
United States, Charlottesville
University of Virginia School of Medicine
Shah, Nirali N.
United States, Rockville
National Cancer Institute Nci
Stetler-Stevenson, Mary A.
United States, Rockville
National Cancer Institute Nci
Yuan, Constance M.
United States, Rockville
National Cancer Institute Nci
Statistics
Citations: 14
Authors: 7
Affiliations: 4
Identifiers
Doi:
10.1002/cyto.b.21591
ISSN:
15524949
e-ISSN:
15524957